safingol has been researched along with Multiple Myeloma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fujimura, Y; Huang, Y; Kay, NE; Kim, YH; Kumazoe, M; Lesnick, C; Miura, D; Shanafelt, TD; Suzuki, T; Tachibana, H; Tsukamoto, S; Ueda, N; Yamada, S; Yamashita, S | 1 |
Alkan, S; Denning, MF; Ergin, M; Izban, KF; Ni, H; Tibudan, SS | 1 |
2 other study(ies) available for safingol and Multiple Myeloma
Article | Year |
---|---|
Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Catechin; Cell Line, Tumor; Death-Associated Protein Kinases; Drug Synergism; Enzyme Activation; Female; Humans; Membrane Microdomains; Mice, Inbred BALB C; Multiple Myeloma; Phosphotransferases (Alcohol Group Acceptor); Receptor Protein-Tyrosine Kinases; Signal Transduction; Sphingomyelin Phosphodiesterase; Sphingosine; Xenograft Model Antitumor Assays | 2015 |
Protein kinase C-delta is commonly expressed in multiple myeloma cells and its downregulation by rottlerin causes apoptosis.
Topics: Acetophenones; Apoptosis; Benzopyrans; Blotting, Western; Down-Regulation; Enzyme Inhibitors; Humans; Multiple Myeloma; Protein Kinase C; Protein Kinase C-delta; Sphingosine; Tumor Cells, Cultured | 2003 |